File downloaded on 2026-11-03
Source URL: https://medicines.health.europa.eu/veterinary/en/600000041013

Coglapix suspension for injection for pigs

Authorised

- Actinobacillus pleuropneumoniae, APX III toxoid
- Actinobacillus pleuropneumoniae, APX I toxoid
- Actinobacillus pleuropneumoniae, APX II toxoid

Product identification

Medicine name:
Coglapix suspension for injection for pigs

Active substance:
Actinobacillus pleuropneumoniae, APX III toxoid

Actinobacillus pleuropneumoniae, APX I toxoid

Actinobacillus pleuropneumoniae, APX II toxoid

Target species:
Pig

Route of administration:
Intramuscular use

Product details

Active substance and strength:
Actinobacillus pleuropneumoniae, APX III toxoid

6.80 enzyme-linked immunosorbent assay unit/millilitre / 2.00 millilitre(s)

Actinobacillus pleuropneumoniae, APX I toxoid
28.90 enzyme-linked immunosorbent assay unit/millilitre / 2.00 millilitre(s)

Actinobacillus pleuropneumoniae, APX II toxoid
16.70 enzyme-linked immunosorbent assay unit/millilitre / 2.00 millilitre(s)

Pharmaceutical form:
Suspension for injection

Withdrawal period by route of administration:
Intramuscular use:

- **Pig**
  - Meat and offal. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI09AB07

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Sweden

Available in:
Sweden

Package description:
Cardboard box containing 1 vial of 100 ml
Cardboard box containing 5 vial of 100 ml

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:
Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)

Marketing authorisation holder:
Ceva Sante Animale

Marketing authorisation date:
10/12/2015

Manufacturing sites for batch release:
Ceva-Phylaxia Zrt.

Responsible authority:
Swedish Medical Products Agency

Authorisation number:
51108

Date of authorisation status change:
10/12/2015

Reference member state:
Hungary

Procedure number:
HU/V/0120/001

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Estonia Finland Germany Greece Iceland Ireland Italy Latvia Lithuania Netherlands Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents

Labelling

This document does not exist in this language (English). You can find it in another language below.